? While industry-sponsored wellness platforms like “The Calm Collective” may raise awareness about endocannabinoid system biology, clinicians should recognize that commercial entities have inherent incentives to expand cannabis use cases that may outpace rigorous clinical evidence. The endocannabinoid system’s legitimate role in homeostasis is well-established, but translating this basic science into clinical recommendations for patients requires robust controlled trials, particularly regarding efficacy, dosing, and long-term safety—data that remain sparse for many proposed indications. Marketing wellness hubs as repositories of “protocol science” risks blurring the line between scientifically validated interventions and aspirational claims, especially given state-level variability in cannabis regulation and the lack of FDA oversight for most products. Clinicians caring for patients interested in cannabis for anxiety, pain, or other conditions should independently evaluate published literature through PubMed and established guidelines rather than

FAQ

This News item was assembled from structured source metadata and pipeline scoring.